ESR1 and breast carcinoma: Although the well-established and effective endocrine therapy has provided millions of women with ER+ breast cancer with targeted treatment option [20, 23], most patients with metastatic disease would unfortunately and inevitably develop resistance to the drugs [28, 29], which has become a major clinical challenge in the treatment of this disease.